{"filing":{"accession_number":"0001764013-26-000106","cik":"0001764013","ticker":"IMVT","company_name":"Immunovant, Inc.","form":"8-K","filing_date":"2026-09-03","report_date":"2026-09-02","primary_document":"imvt-20260902.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000106/imvt-20260902.htm"},"events":[{"id":31670,"run_id":29071,"accession_number":"0001764013-26-000106","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure reports the results of Immunovant's 2026 Annual Meeting of Stockholders held on September 2, 2026, including voting outcomes on three proposals: election of three directors (Jacob Bauer, Douglas Hughes, and Robert Susman), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies for each proposal are the core content of the filing, which is the textbook definition of shareholder vote results disclosure.","company_name":"Immunovant, Inc.","ticker":"IMVT","filing_date":"2026-09-03","form":"8-K","submitted_at":null,"items":[{"id":34615,"accession_number":"0001764013-26-000106","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Immunovant's 2026 Annual Meeting of Stockholders held on September 2, 2026, including voting outcomes on three proposals: election of three directors (Jacob Bauer, Douglas Hughes, and Robert Susman), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies for each proposal are the core content of the filing, which is the textbook definition of shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T21:08:04.712981+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34615,"accession_number":"0001764013-26-000106","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Immunovant's 2026 Annual Meeting of Stockholders held on September 2, 2026, including voting outcomes on three proposals: election of three directors (Jacob Bauer, Douglas Hughes, and Robert Susman), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies for each proposal are the core content of the filing, which is the textbook definition of shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T21:08:04.712981+00:00","company_name":"Immunovant, Inc.","ticker":"IMVT","filing_date":"2026-09-03"}]}